NCT04135300 - Gene Therapy for Chinese Hemophilia B | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 16, 2019

Primary Completion Date

January 7, 2022

Study Completion Date

January 7, 2022

Conditions

Hemophilia B

Interventions

GENETIC

Single dose intravenous injection of BBM-H901

Single dose intravenous infusion of BBM-H901, an adeno-associated viral (AAV) vector designed to drive expression of the human factor IX (hFIX) transgene in liver. The dose of BBM-H901 will be 5x10'12 vg/Kg.

Trial Locations (1)

300020

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors

collaborator

East China University of Science and Technology

OTHER

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER